Abstracts Archive - Page 590 of 2425 - ACR Meeting Abstracts

Abstract Number: 0568 • ACR Convergence 2021
Construction of the Veterans Affairs National Rheumatoid Arthritis Database (VANRAD)
Amy Joseph¹, Jodi Yanagida¹, Xinliang Huang¹, Prabha Ranganathan¹, Melissa Laurie², Hong Xian¹ and Seth Eisen¹, ¹VA St. Louis Health Care System, St. Louis, MO, ²Bristol Myers Squibb, Princeton, NJ
Background/Purpose: The Department of Veterans Affairs (DVA) provides comprehensive medical care at minimal or no cost to 9 million veterans annually through 170 medical centers…
Abstract Number: 0567 • ACR Convergence 2021
Determinants of Health-Related Quality of Life in Spondyloarthritis and Comparison with Chronic Low Back Pain – Results from a Nation-Wide Study
Helena Santos¹, Ana Rita Henriques², Ana Maria Rodrigues³, Jaime Branco³ and Helena Canhao³, ¹Portuguese Institute of Rheumatology, Lisbon, Portugal, ²EpiDoC Unit, Comprehensive Health Research Centre (CHRC), Lisbon, Portugal, ³EpiDoC Unit, CEDOC, NOVA Medical School, Comprehensive Health Research Centre (CHRC), Lisbon, Portugal
Background/Purpose: Spondyloarthritis (SpA) causes pain, fatigue, stiffness, loss of physical function and impaired health-related quality of life (HRQoL).This study aims to: 1) to compare HRQoL…
Abstract Number: 0562 • ACR Convergence 2021
Inpatient Epidemiology and Resource Utilization of Ankylosing Spondylitis: National Inpatient Sample 2018
Patompong Ungprasert¹, Thanat Chaikijurajai², Karn Wijarnpreecha³ and Paul Kroner³, ¹Cleveland Clinic, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH, ³Mayo Clinic Florida, Jacksonville, FL
Background/Purpose: Little is known about inpatient epidemiology, economic burden and resource utilization of patients with ankylosing spondylitis (AS). The current study aims to describe those…
Abstract Number: 0573 • ACR Convergence 2021
Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 and Then to GP1111
Hafsah Nabi¹, Bente Glintborg², Anne Gitte Loft³, Oliver Hendricks⁴, Jens Kristian Pedersen⁵, Søren Andreas Just⁶, Rabiah Ahmed⁷, Kamilla Danebod⁷, Heidi Munk⁸, Ada Colic⁹, Asta Linauskas¹⁰, Dorte Vendelbo Jensen¹¹, Johnny Raun¹², Jolanta Grydehøj¹³, Louise Brot Christensen¹⁴, Natalia Manilo¹⁵, Niels Lomborg¹⁶, Salome Kristensen¹⁷, Frank Mehnert¹⁸, Niels Steen Krogh¹⁹ and Merete Hetland²⁰, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark, ²COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Glostrup, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Snderborg, Denmark, ⁵Section of Rheumatology, Department of Medicine, Svendborg Hospital – Odense University Hospital, Svendborg, Denmark, ⁶Section of Rheumatology, Dept. of Medicine, Svendborg Hospital, Svendborg, Denmark, ⁷Department of Rheumatology, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen University Hospital, Glostrup, Copenhagen, Denmark, ⁸Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁹Department of Rheumatology, Zealand University Hospital, Køge, Denmark, ¹⁰Department of Rheumatology, North Denmark Regional Hospital, Hjoerring, Denmark, ¹¹Department of Internal Medicine, Rønne Hospital, Rønne, Denmark, ¹²Department of Rheumatology, Sygehus Lillebælt, Fredericia, Denmark, ¹³Department of Rheumatology, Holstebro Hospital, Holstebro, Denmark, ¹⁴Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Gentofte, Denmark, ¹⁵Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, ¹⁶Department of Rheumatology, Vejle Hospital Lillebælt, Vejle, Odense C, Denmark, ¹⁷Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹⁸Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, ¹⁹ZiteLab ApS, Copenhagen, Denmark, Frederiksberg, Denmark, ²⁰DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark
Background/Purpose: In routine care, biosimilar to biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of…
Abstract Number: 0572 • ACR Convergence 2021
Circulating Cytokines and Chemokines Are Associated with the Risk of Incident Cardiovascular Disease in Rheumatoid Arthritis Independent of Conventional Disease Activity Measures
Tate Johnson¹, Michael Duryee², Carlos Hunter², Punyasha Roul², Yangyuna Yang², Joshua Baker³, Geoffrey Thiele², Ted Mikuls² and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death in rheumatoid arthritis (RA). While chronic inflammation contributes to CVD pathogenesis, the role of specific…
Abstract Number: 0570 • ACR Convergence 2021
A Narrowed, but Persistent Mortality Gap: A National, Matched Cohort Study in U.S. Veterans with Rheumatoid Arthritis from 2000-2017
Tate Johnson¹, Yangyuna Yang², Punyasha Roul², Brian Sauer³, Joshua Baker⁴, Ted Mikuls² and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Utah, Salt Lake City, UT, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Rheumatoid arthritis (RA) is recognized to increase the risk of premature death. The impact of RA on survival varies across causes of death, though…
Abstract Number: 0574 • ACR Convergence 2021
Prevalence and Early Progression of Lung Diseases in Patients with Recently-Diagnosed Rheumatoid Arthritis: A Prospective Cohort Study
Tina Mahajan¹, Daniel Hershberger¹, Matt Devries², Punyasha Roul¹, Yangyuna Yang¹, Sherrie Edwards¹, Geoffrey Thiele¹, Ted Mikuls¹, James O'Dell¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha
Background/Purpose: Several types of lung diseases complicate the rheumatoid arthritis (RA) disease course such as interstitial lung disease (ILD) and obstructive lung diseases. The prevalence…
Abstract Number: 0576 • ACR Convergence 2021
Associations of the MUC5B Promoter Variant with Timing of Articular Diagnosis and Interstitial Lung Disease in Rheumatoid Arthritis
Gregory McDermott¹, Ritu Gill², Staci Gagne³, Suzanne Byrne³, Weixing Huang³, Jing Cui⁴, Lauren Prisco⁵, Alessandra Zaccardelli³, Lily Martin³, Nancy Shadick⁶, Paul Dellaripa³, Tracy Doyle⁷ and Jeffrey Sparks³, ¹Brigham and Women's Hospital, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Pound Ridge, MA, ⁶Brigham & Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: The common promoter variant of MUC5B (G >T, rs35705950) is associated with increased mucin 5B production in lung parenchyma and is an established genetic…
Abstract Number: 0575 • ACR Convergence 2021
World Mortality of Spondyloarthritis and Inflammatory Bowel Diseases in 2015 and Its Evolution Between 2001 and 2015
Olivier Fakih, Clement Prati, Daniel Wendling and Frank Verhoeven, Service de rhumatologie, CHU de Besançon, Besançon, France
Background/Purpose: There is little epidemiological data on mortality in spondyloarthritis (SpA). This study aimed to determine countries’ mortality rates of ankylosing spondylitis (AS) and psoriatic…
Abstract Number: 0571 • ACR Convergence 2021
The National Incidence of Clinically Diagnosed Psoriatic Arthritis in Sweden 2014-2016
Sofia Exarchou¹, Daniela Di Giuseppe², Gerd-Marie Alenius³, Eva Klingberg⁴, Valgerdur Sigurdardottir⁵, Sara Wedrén⁶, Ulf Lindström⁷, Carl Turesson⁸, Lennart Jacobsson⁷, Johan Askling² and Johan Karlsson Wallman⁹, ¹Lund University, Malmö, Sweden, ²Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ³Umeå University, Umeå, Sweden, Umeå, Sweden, ⁴University of Gothenburg, Gothenburg, Sweden and Sahlgrenska University Hospital, Gothenburg, Sweden, ⁵Uppsala University, Uppsala, Sweden and Falun Hospital, Falun, Sweden, ⁶Karolinska Institutet, Stockholm, Sweden and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁷University of Gothenburg, Gothenburg, Sweden, ⁸Lund University, Malm, Sweden, ⁹Lund University and Skane University Hospital, Hjarup, Sweden
Background/Purpose: Psoriatic arthritis (PsA) incidence estimates vary considerably, and nationwide estimates are sparse. In Sweden, PsA is typically diagnosed in specialized care, although a limited…
Abstract Number: 0565 • ACR Convergence 2021
Increased Risk for Inflammatory Arthritis in Veterans with Depression or Anxiety
Brian Breviu¹, Shaobo Pei¹, Matthew Kirkpatrick², Bingjian Feng¹ and Jessica Walsh³, ¹Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT
Background/Purpose: Depression and anxiety are common in patients with inflammatory arthritis (IA), and have been reported as risk factors for various inflammatory diseases. The study…
Abstract Number: 0546 • ACR Convergence 2021
Integrated Analysis of Dermal Blister Fluid Proteomics and Genome-wide Skin Gene Expression Gives New Insight into Pathogenesis of Systemic Sclerosis
Kristina Clark¹, Eszter Csomor², Corrado Campochiaro³, Adam Taylor⁴, Yee Voan Teo², Katherine Nevin², Mary Morse², Voon Ong⁵, Emma Derrett-Smith⁶, Nicolas Wisniacki², Shaun Flint² and Christopher Denton⁷, ¹University College London, London, United Kingdom, ²GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ³Royal Free Hospital London, London, United Kingdom, ⁴GlaxoSmithKline, London, United Kingdom, ⁵University College London Medical School Royal Free Campus, London, United Kingdom, ⁶University College London Division of Medicine, London, United Kingdom, ⁷University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Suction blister fluid provides a unique opportunity to analyse the dermal microenvironment of SSc. We report an integrated analysis of proteomic data from dermal…
Abstract Number: 0517 • ACR Convergence 2021
TPMT and NUDT15 Genotype and Azathioprine Myelotoxicity in Patients with Inflammatory Conditions: Results from Real-World Clinical Practice
Alyson Dickson¹, Laura Daniel², Jacy Zanussi¹, Wei-Qi Wei¹, Dale Plummer¹, William Dupont³, Ge Liu¹, Prathima Anandi¹, Tyler Reese⁴, Kelly Birdwell¹, Vivian Kawai⁵, Adriana Hung¹, Qiping Feng¹, Nancy J. Cox¹, C. Michael Stein¹ and Cecilia Chung¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Pegram, TN, ³Vanderbilt University, Nashville, TN, ⁴Vanderbilt University Medical Center, Madison, TN, ⁵Vanderbilt Universty Medical Center, Nashville, TN
Background/Purpose: Azathioprine is frequently used for the treatment of several inflammatory conditions. However, treatment is often limited by adverse events, in particular myelotoxicity. Both thiopurine-S-methyltransferase…
Abstract Number: 0454 • ACR Convergence 2021
Lupus Nephritis Mortality in the United States, 1999-2019: Profound Disparities by Race/Ethnicity and Place of Residence and a Recent Worsening Trend
Eric Yen¹, Snehin Rajkumar¹, Rohan Sharma¹ and Ram Singh², ¹University of California Los Angeles, Los Angeles, CA, ²University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Mortality from SLE has improved over the last two decades, but remains disproportionately high relative to general population mortality. Lupus nephritis (LN) occurs in…
Abstract Number: 0329 • ACR Convergence 2021
Racial and Ethnic Disparities in Risk of End-Organ Disease Following SLE Diagnosis in a Multi-Ethnic Cohort
ALFREDO AGUIRRE¹, Andrea Seet¹, Laura Trupin², Patricia Katz¹, Kamil Barbour³, Cristina Lanata⁴, Maria Dall'Era⁵ and Jinoos Yazdany¹, ¹University of California San Francisco, San Francisco, CA, ²UC San Francisco, San Francisco, CA, ³Centers for Disease Control, Atlanta, GA, ⁴University of California San Francisco, Moss Beach, CA, ⁵University of California San Francisco, Corte Madera, CA
Background/Purpose: Racial and ethnic minorities experience a disproportionate burden of systemic lupus erythematosus (SLE) as well as earlier development of lupus manifestations as compared to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].